X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis Fact Sheet, Novartis Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis Fact Sheet   (NVRT)

Here is the latest financial fact sheet of Novartis. For more details, see the Novartis quarterly results and Novartis share price and chart. For a sector overview, read our pharmaceuticals sector report.

NOVARTIS Price History

Price Rs 629.9
Mkt Cap Rs m 211,306
Vol '000 28.8
P/E X 369.3
P/CF X 105.3
EPS (TTM) Rs 1.7
% ch % -4.6
No. of shares m 335.46
% ch week % -1.8
% ch 1-mth % 1.5
% ch 12-mth % -12.0
52 week H/L Rs 758.0/615.0
(As on Jul 28, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NOVARTIS Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
NOVARTIS EQUITY SHARE DATA
High Rs944934605760982 
Low Rs617565361438556 
Sales per share (Unadj.) Rs264.2282.7269.8273.3252.9 
Earnings per share (Unadj.) Rs47.637.530.824.862.1 
Diluted earnings per shareRs4.53.62.92.45.9 
Cash flow per share (Unadj.) Rs48.438.632.026.063.3 
Dividends per share (Unadj.) Rs10.0010.0010.0010.0010.00 
Adj. dividends per shareRs0.950.950.950.950.95 
Dividend yield (eoy) %1.31.32.11.71.3 
Book value per share (Unadj.) Rs255.9281.7300.8313.5363.6 
Adj. book value per shareRs24.426.828.729.934.6 
Shares outstanding (eoy) m31.9631.9631.9631.9631.96 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x3.02.71.82.23.0 
Avg P/E ratio x16.420.015.724.212.4 
P/CF ratio (eoy) x16.119.415.123.012.2 
Price / Book Value ratio x3.02.71.61.92.1 
Dividend payout %21.026.732.440.416.1 
Avg Mkt Cap Rs m24,94523,95415,43319,14724,580 
No. of employees `0001.41.41.31.20.8 
Total wages/salary Rs m1,3771,6231,7422,0001,801 
Avg. sales/employee Rs Th6,212.66,555.66,663.37,236.010,748.9 
Avg. wages/employee Rs Th1,013.11,177.81,346.11,657.22,395.2 
Avg. net profit/employee Rs Th1,118.6868.9761.4655.42,641.1 
NOVARTIS INCOME DATA
Net Sales Rs m8,4439,0348,6228,7348,083 
Other income Rs m8408329511,076829 
Total revenues Rs m9,2839,8669,5749,8108,913 
Gross profit Rs m1,439900-13-39234 
Depreciation Rs m2736374037 
Interest Rs m52322 
Profit before tax Rs m2,2471,6948999961,025 
Minority Interest Rs m00000 
Prior Period Items Rs m38439616517 
Extraordinary Inc (Exp) Rs m000-631,696 
Tax Rs m730581310306752 
Profit after tax Rs m1,5201,1979857911,986 
Gross profit margin %17.010.0-0.2-0.42.9 
Effective tax rate %32.534.334.530.773.4 
Net profit margin %18.013.311.49.124.6 
NOVARTIS BALANCE SHEET DATA
Current assets Rs m9,32710,33510,61010,63412,678 
Current liabilities Rs m1,9312,1222,1222,1072,433 
Net working cap to sales %87.690.998.597.6126.7 
Current ratio x4.84.95.05.05.2 
Inventory Days Days3445444233 
Debtors Days Days3033333522 
Net fixed assets Rs m102102798569 
Share capital Rs m160160160160160 
"Free" reserves Rs m8,0178,8419,4529,85911,460 
Net worth Rs m8,1799,0029,61410,02011,621 
Long term debt Rs m10000 
Total assets Rs m10,16411,41212,02112,46114,400 
Interest coverage x417.1771.1334.0475.1570.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.80.80.70.70.6 
Return on assets %15.010.58.26.413.8 
Return on equity %18.613.310.27.917.1 
Return on capital %27.619.813.511.023.6 
Exports to sales %0.50.60.90.90.7 
Imports to sales %17.719.421.814.218.6 
Exports (fob) Rs m4550798060 
Imports (cif) Rs m1,4961,7491,8771,2441,503 
Fx inflow Rs m86125144149186 
Fx outflow Rs m1,8672,1372,3351,6451,821 
Net fx Rs m-1,781-2,012-2,191-1,497-1,635 
NOVARTIS CASH FLOW
From Operations Rs m 747 74 -46 -596 2,531 
From Investments Rs m -427 -161 222 7,189 -8,270 
From Financial Activity Rs m -375 -373 -378 -377 -386 
Net Cashflow Rs m -55 -460 -202 6,217 -6,125 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 2.0%
FIIs 1.6%
ADR/GDR 0.0%
Free float 21.5%
Shareholders 41,647
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Sandoz House, Shivsagar Estate, Dr. Annie Besant Road, Mumbai-18
E-MAIL girish.tekchandani@novartis.com WEB www.novartis.in
TELEPHONE (022) 2495 8400 FAX (022) 2495 0221
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Sharepro Serv., 13 AB, Samhita Warehousing, Andheri (E), Mumbai-72
AUDITOR Lovelock and Lewes
CHM: C. Snook COMP SEC: Girish Tekchandani YEAR OF INC: 1947 BSE CODE: 500672 FV (Rs): 5 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   ALEMBIC PHARMA  WOCKHARDT LTD.  SANOFI INDIA  AUROBINDO PHARMA  VENUS REMEDIES  

Compare NOVARTIS With:   ALEMBIC PHARMA  WOCKHARDT LTD.  SANOFI INDIA  AUROBINDO PHARMA  VENUS REMEDIES  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Buoyant(RoundUp)

Global financial markets ended the week in the green with most of the indices ending in the positive territory. Barring Germany and Japan, all the indices were gainers in the week gone by.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Sensex 40,000: Why You Must Dump 'Arthritis' Stocks(The 5 Minute Wrapup)

Jul 21, 2017

Identify and get rid of the 'arthritis stocks' to get the real profits from Sensex 40,000.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

Trade the Markets like Roger Federer Plays Tennis(Daily Profit Hunter)

Jul 19, 2017

Trading is one of the most competitive fields in the world today. To win, you must adopt the mindset of a Grand Slam champion.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

Why Keeping Unrealistic Expectations From Investments Is Stupid!(Outside View)

Jul 18, 2017

When investing, keeping realistic returns is necessary and it is not the only thing you should look at.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NOVARTIS

NOVARTIS - GSK PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS